ABELCET

LOE Approaching

amphotericin b

NDAINJECTIONINJECTABLE, LIPID COMPLEXPriority Review
Approved
Nov 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

Mechanism of Action Amphotericin B, the active ingredient of amphotericin B liposome for injection, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. It forms transmembrane channels leading to alterations in cell permeability through which monovalent…

Clinical Trials (5)

NCT06525389Phase 3Not Yet Recruiting

Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)

Started Apr 2026
428 enrolled
Talaromycosis
NCT07357038N/ARecruiting

A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis

Started Sep 2025
38 enrolled
Fungal Disease
NCT06977490N/ACompleted

Human Bioequivalence Study of Amphotericin B Liposome for Injection

Started May 2025
NCT05814432Phase 3Recruiting

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Started Jan 2025
279 enrolled
Disseminated Histoplasma Capsulatum InfectionAIDS and InfectionsImmunosuppression+1 more
NCT01945281Phase 2Terminated

Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of Invasive Candidiasis in Neonates and Infants (MK-0991-064)

Started Jan 2014
51 enrolled
Candidiasis, Invasive